mitoxantrone has been researched along with Hodgkin Disease in 58 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was undertaken to systematically evaluate the agreement rates among single photon emission computed tomography using gallium-67 (Ga-67 SPECT), lymphangiography (LAG), and computed axial tomography (CT) scan findings for Hodgkin disease and to correlate radiologic findings with clinical outcome." | 9.09 | Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome. ( Allen, PK; Choe, JG; Cox, JD; Edmund, E; Ha, CS; Kong, JS; Oh, YK, 2000) |
| "We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation." | 9.07 | Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ( Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993) |
| "As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease." | 9.07 | Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. ( Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ, 1991) |
| "Two phase II trials of mitoxantrone in refractory malignant lymphoma have been conducted." | 7.67 | Mitoxantrone in malignant lymphoma. ( Gams, RA; Posner, L; Steinberg, J, 1984) |
| "The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule." | 7.66 | Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. ( Balcerzak, SP; Coltman, CA; McDaniel, TM; Morrison, FS; Von Hoff, DD, 1983) |
| "This study was undertaken to systematically evaluate the agreement rates among single photon emission computed tomography using gallium-67 (Ga-67 SPECT), lymphangiography (LAG), and computed axial tomography (CT) scan findings for Hodgkin disease and to correlate radiologic findings with clinical outcome." | 5.09 | Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome. ( Allen, PK; Choe, JG; Cox, JD; Edmund, E; Ha, CS; Kong, JS; Oh, YK, 2000) |
| "We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation." | 5.07 | Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ( Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993) |
| "As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease." | 5.07 | Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. ( Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ, 1991) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "The objective of this research was to determine whether Novantrone, Oncovin, Velban, and Prednisone (NOVP) combination chemotherapy for Hodgkin's disease increases the frequencies of the specific types of aneuploid sperm that might elevate the risk of fathering a child with one of the major clinical aneuploidy syndromes, i." | 3.72 | NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. ( Bishop, JB; Frias, S; Hagemeister, FB; Lowe, XR; Meistrich, ML; Shelby, MD; Van Hummelen, P; Wyrobek, AJ, 2003) |
| " Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone." | 3.67 | [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. ( Hattori, M; Honda, T; Sampi, K, 1984) |
| "Two phase II trials of mitoxantrone in refractory malignant lymphoma have been conducted." | 3.67 | Mitoxantrone in malignant lymphoma. ( Gams, RA; Posner, L; Steinberg, J, 1984) |
| "The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule." | 3.66 | Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. ( Balcerzak, SP; Coltman, CA; McDaniel, TM; Morrison, FS; Von Hoff, DD, 1983) |
| "Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, mainly because of a lack of prospective randomized studies, due to difficulties in enrolling patients." | 2.82 | Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). ( Angelucci, E; Bari, A; Bellei, M; Ciccone, G; Ilariucci, F; Levis, A; Liberati, AM; Mannina, D; Merli, F; Monagheddu, C; Rota Scalabrini, D; Salvi, F; Stelitano, C; Tamiazzo, S; Vallisa, D; Vitolo, U; Zallio, F, 2016) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses." | 2.69 | [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998) |
| "Mitoxantrone is an active agent in lymphoma that is not generally used in first-line treatment." | 2.69 | CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma. ( Kraszewska, E; Krzyzanowska, JB; Lampka, E; Meder, J; Miśkiewicz, Z; Romejko-Jarosińska, J; Walewski, J, 2000) |
| "Modern treatment plans for early staged Hodgkin's disease must focus on optimal disease-free survival results without laparotomy, minimal acute toxicity, and reduced long-term complications." | 2.67 | NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. ( Cabanillas, F; Fuller, L; Hagemeister, FB; McLaughlin, P; Rodriguez, M; Romaguera, J; Swan, F, 1992) |
| "Nine Hodgkin lymphoma (HL) patients provided 20 semen samples before, during, and after NOVP therapy (Novantrone, Oncovin, Velban and Prednisone) and radiation therapy that produced scattered gonadal doses from <0." | 1.56 | Meiotic susceptibility for induction of sperm with chromosomal aberrations in patients receiving combination chemotherapy for Hodgkin lymphoma. ( Frias, S; Meistrich, ML; Van Hummelen, P; Wyrobek, AJ, 2020) |
| "Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT)." | 1.43 | High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. ( Aurer, I; Bašić-Kinda, S; Dotlić, S; Dujmović, D; Kralik, M; Labar, B; Mazić, S; Mitrović, Z; Nemet, D; Radman, I; Šantek, F; Sertić, D, 2016) |
| "More recently, a number of cases of panniculitis and subcutaneous inflammatory oedema have been described." | 1.37 | [Severe skin reaction with mucous membrane inflammation during MINE chemotherapy]. ( Camus, M; Guillet, G; Hainaut-Wierzbicka, E; Levillain, P; Lopez, L; Saulnier, JP, 2011) |
| "Hodgkin lymphoma is a highly curable disease." | 1.34 | [Hodgkin lymphoma in Chile: experience of the national adult cancer program]. ( Aspillaga, A; Cabrera, ME; Cerda, B; García, H; Hales, C; León, A; Lois, V; Meneses, P; Merino, C; Oliva, J; Peña, K; Rojas, H; Rosas, J; Rossle, A; Vittini de, C, 2007) |
| "In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low incidence of HL in the elderly, prospective studies are lacking and the best treatment strategy is difficult to define." | 1.32 | VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. ( Adamo, F; Ambrosetti, A; Angelucci, E; Anselmo, AP; Bertini, M; Boccadoro, M; Cavalieri, E; Gallo, E; Gavarotti, P; Genua, A; Levis, A; Liberati, M; Mandelli, F; Pavone, V; Pietrasanta, D; Ricetti, MM; Salvi, F; Scalabrini, DR; Vitolo, U, 2004) |
| " TMJ is a safe and effective regimen when used as a part of autologous stem cell transplant for patients with HD and NHL." | 1.32 | High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. ( Ahmed, T; Hoang, A; Kancherla, R; Liu, D; Qureshi, Z; Seiter, K; Waheed, F, 2004) |
| "Intracranial Hodgkin's disease is very rare and is often a terminal event." | 1.30 | Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. ( Agarwal, V; Ashigbi, MY; Bello, J; Venkatraj, U; Wiernik, PH, 1997) |
| "Anderson Cancer Center for treatment of Hodgkin's disease [HD]." | 1.29 | A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity. ( Bailey, NM; Cabanillas, FF; Fuller, LM; Gabriel, GJ; Hagemeister, FB; Kattan, MW; Liang, JC; Wang, RY, 1993) |
| "Cardiotoxicity is a well recognized side effect of anthracyclines (doxorubicin and epirubicin) or antracenadiones (mitoxantrone) at cumulative or high doses." | 1.29 | Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. ( Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ, 1993) |
| "Management of Hodgkin's disease (HD) and large mediastinal adenopathy (LMA) usually includes intensive chemotherapy (CT) with or without radiation therapy (XT) regardless of stage." | 1.29 | Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. ( Allen, PK; Besa, P; Cabanillas, F; Cox, JD; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, A; Swan, F, 1994) |
| "Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents." | 1.29 | Are alkylating agents a necessary component in the therapy of Hodgkin's disease. ( Hagemeister, FB, 1993) |
| "In stage III and IV Hodgkin's disease, for example, an age-adjusted COPP regimen may be adopted." | 1.28 | [Treatment of elderly patients with hematological malignancies]. ( Mizoguchi, H; Saito, H, 1992) |
| "Responses of the Hodgkin's disease to this therapy were favourable but short-lived." | 1.28 | High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Baglin, TP; Flavell, DJ; Flavell, SU; Lim, SH; Marcus, RE; Wimperis, JZ, 1992) |
| " From June 1988 to December 1989, 27 previously untreated patients with early-staged Hodgkin's disease with adverse features for disease-free survival received combined-modality therapy." | 1.28 | NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; Liang, JC; McLaughlin, P; Meistrich, ML; Redman, JR; Rodríguez, MA; Romaguera, JE; Swan, F; Velásquez, WS, 1990) |
| " Modifications in timing and dosage and the addition of hematopoietic growth factors will be evaluated in subsequent trials." | 1.28 | Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group. ( Hiddemann, W; Kirchner, H; Koch, P; Maschmeyer, G; Ollech-Chwoyka, J; Pflüger, KH; Pfreundschuh, M; Schmitz, N; Tirier, C; Wagner, T, 1990) |
| "One of 11 patients with Hodgkin's disease, 2 of 12 with favorable-histology non-Hodgkin's lymphoma, 4 of 27 with unfavorable-histology non-Hodgkin's lymphoma, and 1 of 11 with chronic lymphocytic leukemia showed a response." | 1.27 | Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial. ( Bartolucci, AA; Gams, RA; Keller, JW; Omura, GA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (13.79) | 18.7374 |
| 1990's | 25 (43.10) | 18.2507 |
| 2000's | 20 (34.48) | 29.6817 |
| 2010's | 4 (6.90) | 24.3611 |
| 2020's | 1 (1.72) | 2.80 |
| Authors | Studies |
|---|---|
| Frias, S | 2 |
| Van Hummelen, P | 2 |
| Meistrich, ML | 5 |
| Wyrobek, AJ | 2 |
| Zallio, F | 1 |
| Tamiazzo, S | 1 |
| Monagheddu, C | 1 |
| Merli, F | 1 |
| Ilariucci, F | 1 |
| Stelitano, C | 1 |
| Liberati, AM | 1 |
| Mannina, D | 1 |
| Vitolo, U | 3 |
| Angelucci, E | 2 |
| Rota Scalabrini, D | 1 |
| Vallisa, D | 1 |
| Bellei, M | 1 |
| Bari, A | 1 |
| Ciccone, G | 1 |
| Salvi, F | 2 |
| Levis, A | 4 |
| Aurer, I | 1 |
| Nemet, D | 1 |
| Mitrović, Z | 1 |
| Dujmović, D | 1 |
| Bašić-Kinda, S | 1 |
| Radman, I | 1 |
| Sertić, D | 1 |
| Šantek, F | 1 |
| Kralik, M | 1 |
| Dotlić, S | 1 |
| Mazić, S | 1 |
| Labar, B | 1 |
| Gobbi, PG | 2 |
| Valentino, F | 1 |
| Lambelet, P | 1 |
| Perfetti, V | 1 |
| Bergamaschi, G | 1 |
| Girino, M | 1 |
| Corazza, GR | 1 |
| Camus, M | 1 |
| Hainaut-Wierzbicka, E | 1 |
| Levillain, P | 1 |
| Saulnier, JP | 1 |
| Lopez, L | 1 |
| Guillet, G | 1 |
| Chen, DB | 1 |
| Shen, DH | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Lowe, XR | 1 |
| Hagemeister, FB | 12 |
| Shelby, MD | 1 |
| Bishop, JB | 1 |
| Adiga, GU | 1 |
| Abebe, L | 1 |
| Wiernik, PH | 2 |
| Tarella, C | 1 |
| Cuttica, A | 1 |
| Liberati, M | 2 |
| Di Nicola, M | 1 |
| Cortelazzo, S | 1 |
| Rosato, R | 1 |
| Rosanelli, C | 1 |
| Di Renzo, N | 1 |
| Musso, M | 1 |
| Pavone, E | 1 |
| Santini, G | 2 |
| Pescarollo, A | 1 |
| De Crescenzo, A | 1 |
| Federico, M | 2 |
| Gallamini, A | 1 |
| Pregno, P | 1 |
| Romano, R | 1 |
| Coser, P | 1 |
| Gallo, E | 2 |
| Boccadoro, M | 2 |
| Barbui, T | 1 |
| Pileri, A | 1 |
| Gianni, AM | 1 |
| Anselmo, AP | 1 |
| Ambrosetti, A | 1 |
| Adamo, F | 1 |
| Bertini, M | 1 |
| Cavalieri, E | 1 |
| Gavarotti, P | 1 |
| Genua, A | 1 |
| Pavone, V | 1 |
| Pietrasanta, D | 1 |
| Ricetti, MM | 1 |
| Scalabrini, DR | 1 |
| Mandelli, F | 1 |
| Chronowski, GM | 2 |
| Wilder, RB | 2 |
| Levy, LB | 1 |
| Atkinson, EN | 1 |
| Ha, CS | 5 |
| Barista, I | 2 |
| Rodriguez, MA | 4 |
| Sarris, AH | 1 |
| Hess, MA | 1 |
| Cabanillas, F | 7 |
| Cox, JD | 5 |
| Ibrahim, D | 1 |
| Smith, MR | 1 |
| Varterasian, M | 1 |
| Karanes, C | 1 |
| Millenson, M | 1 |
| Yeslow, G | 1 |
| Pemberton, P | 1 |
| Lai, P | 1 |
| Abrams, J | 1 |
| Al-Katib, A | 1 |
| Waheed, F | 1 |
| Kancherla, R | 2 |
| Seiter, K | 3 |
| Liu, D | 1 |
| Qureshi, Z | 1 |
| Hoang, A | 1 |
| Ahmed, T | 3 |
| Avilés, A | 4 |
| Neri, N | 1 |
| Nambo, JM | 1 |
| Huerta-Guzman, J | 1 |
| Talavera, A | 2 |
| Cleto, S | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Cabrera, ME | 1 |
| García, H | 1 |
| Lois, V | 1 |
| León, A | 1 |
| Peña, K | 1 |
| Rossle, A | 1 |
| Cerda, B | 1 |
| Rojas, H | 1 |
| Meneses, P | 1 |
| Merino, C | 1 |
| Aspillaga, A | 1 |
| Vittini de, C | 1 |
| Oliva, J | 1 |
| Hales, C | 1 |
| Rosas, J | 1 |
| Moser, K | 1 |
| Pohl, A | 1 |
| Sampi, K | 1 |
| Honda, T | 1 |
| Hattori, M | 1 |
| Gams, RA | 3 |
| Steinberg, J | 2 |
| Posner, L | 1 |
| Keller, JW | 2 |
| Golomb, HM | 2 |
| Dukart, G | 1 |
| Coltman, CA | 2 |
| McDaniel, TM | 2 |
| Balcerzak, SP | 2 |
| Morrison, FS | 2 |
| Von Hoff, DD | 2 |
| Guzmán, R | 2 |
| García, EL | 2 |
| Díaz-Maqueo, JC | 2 |
| Preti, A | 1 |
| McLaughlin, P | 6 |
| Swan, F | 5 |
| Rodriguez, A | 1 |
| Besa, P | 1 |
| Allen, PK | 2 |
| Soto, B | 1 |
| Nambo, MJ | 2 |
| Liang, JC | 2 |
| Bailey, NM | 1 |
| Gabriel, GJ | 1 |
| Kattan, MW | 1 |
| Wang, RY | 1 |
| Cabanillas, FF | 2 |
| Fuller, LM | 3 |
| Schlaifer, D | 2 |
| Attal, M | 2 |
| Huguet, F | 2 |
| Canal, P | 2 |
| Laurent, G | 2 |
| Pris, J | 1 |
| Purugganan, R | 2 |
| Fuller, L | 2 |
| Romaguera, J | 2 |
| Rodriguez, M | 2 |
| Podoloff, DA | 1 |
| Hess, M | 1 |
| Romaguera, JE | 3 |
| Arévila, N | 1 |
| Díaz Maqueo, JC | 1 |
| Gómez, T | 1 |
| García, R | 1 |
| Chatelut, E | 1 |
| Guichard, S | 1 |
| Muller, C | 1 |
| Houin, G | 1 |
| Bugat, R | 1 |
| Lake, D | 1 |
| Feldman, E | 1 |
| Helson, L | 2 |
| Mittelman, A | 2 |
| Puccio, C | 1 |
| Chun, H | 1 |
| Grima, K | 1 |
| Akhtar, T | 2 |
| Lake, DE | 1 |
| Beer, M | 1 |
| Feldman, EJ | 1 |
| Preti, RA | 1 |
| Ascensao, J | 1 |
| Cook, P | 1 |
| Goldberg, R | 1 |
| Coleman, M | 1 |
| Ashigbi, MY | 1 |
| Venkatraj, U | 1 |
| Agarwal, V | 1 |
| Bello, J | 1 |
| Wilson, G | 2 |
| Mathur, K | 1 |
| Lipshultz, LI | 1 |
| Bairey, O | 1 |
| Gabbay, U | 1 |
| Blickstein, D | 1 |
| Stark, P | 1 |
| Prokocimer, M | 1 |
| Epstein, O | 1 |
| Shaklai, M | 1 |
| Lahav, J | 1 |
| Mayer, J | 1 |
| Korístek, Z | 1 |
| Vásová, I | 1 |
| Müllerová, I | 1 |
| Král, Z | 1 |
| Navrátil, M | 1 |
| Klabusay, M | 1 |
| Vorlícek, J | 1 |
| Vodvárka, P | 1 |
| Hejlová, N | 1 |
| Penka, M | 1 |
| Krahulcová, E | 1 |
| Tomíska, M | 1 |
| Adam, Z | 1 |
| Hájek, R | 1 |
| Tormo, M | 1 |
| Terol, MJ | 1 |
| Marugán, I | 1 |
| Solano, C | 1 |
| Benet, I | 1 |
| Garcia-Conde, J | 1 |
| Dubey, P | 1 |
| Mathur, KK | 1 |
| Walewski, J | 1 |
| Krzyzanowska, JB | 1 |
| Kraszewska, E | 1 |
| Lampka, E | 1 |
| Romejko-Jarosińska, J | 1 |
| Miśkiewicz, Z | 1 |
| Meder, J | 1 |
| La Barbera, EO | 1 |
| Chiusolo, P | 1 |
| Laurenti, L | 1 |
| Menichella, G | 1 |
| Di Febo, AL | 1 |
| Piccirillo, N | 1 |
| Sorà, E | 1 |
| Marra, R | 1 |
| Teofili, L | 1 |
| Leone, G | 1 |
| Sica, S | 1 |
| Choe, JG | 1 |
| Kong, JS | 1 |
| Oh, YK | 1 |
| Edmund, E | 1 |
| Hänel, M | 1 |
| Kröger, N | 1 |
| Kroschinsky, F | 1 |
| Birkmann, J | 1 |
| Hänel, A | 1 |
| Herbst, R | 1 |
| Naumann, R | 1 |
| Friedrichsen, K | 1 |
| Ehninger, G | 1 |
| Zander, AR | 1 |
| Fiedler, F | 1 |
| Schlembach, PJ | 1 |
| Jones, D | 1 |
| Younes, A | 1 |
| Chisesi, T | 1 |
| Deliliers, GL | 1 |
| Luminari, S | 1 |
| Linfomi, MB | 1 |
| Saito, H | 1 |
| Mizoguchi, H | 1 |
| Lim, SH | 1 |
| Baglin, TP | 1 |
| Flavell, DJ | 1 |
| Flavell, SU | 1 |
| Wimperis, JZ | 1 |
| Marcus, RE | 1 |
| Crown, JP | 1 |
| Gulati, S | 1 |
| Straus, DJ | 1 |
| Kolitz, J | 1 |
| Heelan, R | 1 |
| O'Brien, J | 1 |
| Lee, BJ | 1 |
| Portlock, C | 1 |
| Bertino, J | 1 |
| Silver, RT | 1 |
| Case, DC | 1 |
| Wheeler, RH | 1 |
| Miller, TP | 1 |
| Stein, RS | 1 |
| Stuart, JJ | 1 |
| Peterson, BA | 1 |
| Rivkin, SE | 1 |
| Phillips, JK | 1 |
| Spearing, RL | 1 |
| Davies, JM | 1 |
| Hay, CR | 1 |
| Parry, H | 1 |
| Nash, JR | 1 |
| Cawley, JC | 1 |
| Velásquez, WS | 1 |
| Redman, JR | 1 |
| Hiddemann, W | 1 |
| Schmitz, N | 1 |
| Pfreundschuh, M | 1 |
| Pflüger, KH | 1 |
| Ollech-Chwoyka, J | 1 |
| Tirier, C | 1 |
| Maschmeyer, G | 1 |
| Kirchner, H | 1 |
| Wagner, T | 1 |
| Koch, P | 1 |
| Bernasconi, C | 1 |
| Omura, GA | 1 |
| Bartolucci, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)[NCT03576378] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2018-08-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Hodgkin Disease
| Article | Year |
|---|---|
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Co | 2003 |
[Recent developments in chemotherapy of malignant diseases].
Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1982 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Dise | 1989 |
21 trials available for mitoxantrone and Hodgkin Disease
| Article | Year |
|---|---|
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2016 |
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarab | 2009 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etoposide; Female; Follow-Up Stu | 2004 |
Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-F | 2005 |
Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD).
Topics: Actuarial Analysis; Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD, or MBVD.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Da | 1995 |
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Topics: Adult; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; M | 1993 |
Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1997 |
Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; H | 1997 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etopos | 1998 |
Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administratio | 1999 |
CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea | 2000 |
MiCMA: an alternative treatment for refractory or recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Female; | 2000 |
Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Citrates; | 2000 |
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Fr | 2001 |
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas | 2002 |
ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Daca | 2002 |
NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Tolerance; Hodgkin D | 1992 |
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hodgk | 1991 |
Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Drug Evaluation; Female; Heart; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; | 1991 |
34 other studies available for mitoxantrone and Hodgkin Disease
| Article | Year |
|---|---|
Meiotic susceptibility for induction of sperm with chromosomal aberrations in patients receiving combination chemotherapy for Hodgkin lymphoma.
Topics: Adult; Adult Germline Stem Cells; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; | 2020 |
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 2016 |
[Severe skin reaction with mucous membrane inflammation during MINE chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Edema; Etoposide; Female | 2011 |
[Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 2011 |
NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21.
Topics: Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 18; Chro | 2003 |
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2003 |
VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 2004 |
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Disease | 2004 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
[Hodgkin lymphoma in Chile: experience of the national adult cancer program].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2007 |
Leukaemia due to mitoxantrone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Europe; Fem | 2007 |
[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
Mitoxantrone in malignant lymphoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Hodgkin Disease; Humans; Lymphoma; Mitoxantr | 1984 |
Mitoxantrone in malignant lymphomas.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Hodgkin Disease; Humans; Intercalating Agent | 1983 |
Mitoxantrone hydrochloride in lymphoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Heart; Hodgkin Disease; Humans; Intercalatin | 1983 |
Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
Topics: Anthraquinones; Drug Evaluation; Hodgkin Disease; Humans; Infusions, Parenteral; Lymphoma; Mitoxantr | 1983 |
Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1994 |
Are alkylating agents a necessary component in the therapy of Hodgkin's disease.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Hodgkin Disease; Human | 1993 |
A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Cycle; Chro | 1993 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chem | 1994 |
Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans; | 1994 |
The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Gallium; Hodgkin Disease; | 1994 |
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Female; Follow-Up St | 1993 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1995 |
Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modalit | 1997 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherap | 1997 |
Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Male; Mi | 2000 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adult; Bone Marrow Transplantation; Etoposide; Female; Heart Diseases; Hodgkin Disease; Humans; Male | 1992 |
VIM-D salvage chemotherapy in Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined M | 1990 |
NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Follow-Up Studies; | 1990 |
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1990 |
Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial.
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Evaluation; Female; Hodgkin Disease; Humans; I | 1987 |